NOMO-1 Cells
USD$375.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
General information
| Description | The NOMO-1 cell line is derived from a 31-year-old female patient diagnosed with acute monocytic leukemia (AML-M5a). This cell line exhibits promonocytic characteristics, making it a robust model for studying monocytic leukemia and differentiation. NOMO-1 cells demonstrate responsiveness to differentiation-inducing agents such as phorbol esters (e.g., 12-o-tetradecanoyl phorbol-13-acetate or TPA), leading to their maturation into macrophage-like cells. Upon differentiation, the cells exhibit increased expression of markers like fibronectin and secretion of interleukins IL-1α and IL-1β, which are critical for immune response and inflammation pathways. These cells also play a pivotal role in studying the coagulation and fibrinolysis systems. NOMO-1 cells secrete tissue factor (TF), plasminogen activator (PA), and plasminogen activator inhibitor (PAI), with the secretion levels modulated by differentiation inducers. TPA treatment enhances the production of TF and PA, particularly the urokinase-type PA (uPA), while also increasing PAI secretion, suggesting NOMO-1's relevance in understanding hemostasis and thrombosis mechanisms in leukemia. Genetically, NOMO-1 cells harbor the t(9;11)(p22;q23) translocation, resulting in the MLL-AF9 fusion gene, which is a hallmark of certain AML subtypes. This translocation drives leukemogenesis by dysregulating gene expression programs associated with hematopoietic differentiation and proliferation. The presence of this translocation makes NOMO-1 a vital tool for exploring MLL-rearranged leukemias and evaluating targeted therapies. |
|---|---|
| Organism | Human |
| Tissue | Bone marrow |
| Disease | Adult acute monocytic leukemia |
| Synonyms | Nomo-1, NOMO1 |
Characteristics
| Age | 31 years |
|---|---|
| Gender | Female |
| Ethnicity | Japanese |
| Morphology | Lymphoblast-like |
| Growth properties | Suspension |
Regulatory Data
| Citation | NOMO-1 (Cytion catalog number 305604) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_1609 |
Biomolecular Data
| Antigen expression | CD3 -, CD4 +, CD13 +, CD14 -, CD15 +, CD19 -, CD33 +, CD34 -, HLA-DR + |
|---|
Handling
| Culture Medium | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| Supplements | Supplement the medium with 10% heat-inactivated FBS |
| Seeding density | 0.5 - 1 x 106 cells/mL |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
| Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|